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Selenium-containing proteins (e.g., glutathione peroxidases) are important antioxidants in 
neuronal defense against oxidative stress.  In this study, the production of amyloid-β (Aβ) 
plaques in the brain of the Tg2576 transgenic mice was investigated under a dietary 
selenium-deficient condition.  The 16-week-old mice were fed a selenium-deficient diet 
(0.004 μg-selenium g−1-diet) or a selenium-adequate diet (0.386 μg-selenium g−1-diet) for 
76-week.  The selenium concentrations of the organs/tissues in the selenium-deficient 
diet-fed mice were significantly decreased in comparison to those in the selenium-adequate 
diet-fed mice; 1.7% of that in the selenium-adequate diet-fed mice in the liver and 43% of that 
in the selenium-adequate diet-fed mice in the brain.  The Aβ plaques formed in the brain 
were fluorescently stained with thioflavin T, and then the obtained images of the brain slices 
were qualitatively analyzed.  The feeding of the selenium-deficient diet to the Tg2576 
transgenic mice resulted in more than a two-fold increase in the total area of the Aβ plaques 
in comparison to that of the selenium-adequate diet.  The elevated Aβ plaque deposition in 
the selenium-deficient mice can be explained as a consequence of decreases in the selenium 
concentration, which suggests that the selenium status is associated with the production 
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and/or the clearance of the Aβ peptide.  The selenium-deficiency could possibly promote the 
onset and/or progression of Alzheimer’s disease (AD) dementia, if the Aβ peptides initiate a 
sequence of events that lead to AD dementia.  Consequently, the results shown here suggest 




The deposition of insoluble plaques containing amyloid-β (Aβ) peptides in the brain 
represents a pathological hallmark feature of Alzheimer’s disease (AD) dementia.  The 
amyloid cascade hypothesis, which posits that the deposition of the Aβ peptide is a central 
event in AD pathology, has dominated research for the past three decades.1  The human brain, 
which claims ∼2% of total body mass, is responsible for ∼20% of total body oxygen 
consumption.2−4  In consequence of the high oxygen demand, the brain inevitably induces the 
generation of large amounts of reactive oxygen species (ROS), which are thought to be 
associated with the onset and/or progression of AD dementia due to the ROS-mediated injury 
to certain brain regions from the early stages of the illness.5−7  Thus, oxidative stress is a key 
feature in the AD patient brain and manifests as lipid peroxidation.   
Selenium is an essential antioxidant nutrient for humans and other higher animal species 
and is incorporated into selenoproteins in the form of selenocysteine that is known as the 21st 
amino acid.8  The brain is the organ that remains selenium replete the longest under 
conditions of selenium deficiency, suggesting that selenium plays a critical role in brain 
functions.  Accumulating papers have pointed out that decreases in selenium-dependent 
glutathione peroxidase (GPx) activity in the brain are associated with the onset of 
neurodegenerative diseases including AD dementia.9−12  In particular, the role of GPx-4 
appears more important than other antioxidant enzymes due to the high lipid content in the 
brain.13,14  In addition, selenoprotein P (SelP),15 which is the brain-specific selenium transport 
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protein in the plasma, is known to be essential for neuronal survival and function16 and is also 
associated with the AD pathology.17  Recently, AD dementia patients were reported to have 
significantly lower selenium concentrations in the plasma, red cells and nails (32.59, 43.74 
and 0.302 μg g−1) compared with the healthy control subjects (50.99, 79.16 and 0.400 μg 
g−1).18   
The purpose of this study was to investigate whether the dietary selenium status affects 
the production of Aβ plaques in the brain.  Experiments were conducted to study the effect 
of dietary selenium deficiency on the Aβ plaque deposition using the Tg2576 transgenic mice.  
So far, scant information on the relevance of selenium status to the production of the Aβ 
plaques in vivo has been reported.19,20  To our best knowledge, this is the first paper showing 
that the dietary selenium-deficiency increases the Aβ plaques formed in the brain of the 




Animals and diets 
 
Female 16-week-old Tg2576 transgenic mice were obtained from Taconic Farms, Inc. 
(Germantown, NY, U.S.A.) and cared for in accordance with the guidelines of Nagasaki 
University on Animal Care.  The mice were randomly divided into two groups (five in each) 
and housed one per cage on a 12 h light/12 h dark schedule at 23 ± 2 °C and 60% relative 
humidity.  The mice were freely fed a selenium-deficient diet [Oriental Yeast Co. Ltd., 
Tokyo, Japan, Nutrient contents (% by weight): torula yeast, 30; sucrose, 55.7; lard, 5; liver 
oil, 3; minerals, 5; vitamins, 0.9; methionine, 0.3; choline chloride, 0.2]21 or a 
selenium-adequate regular breeding diet CE-2 (Clea Japan, Inc., Tokyo, Japan) for 76 weeks.  
Selenium concentrations of the selenium-deficient and selenium-adequate diets used in this 
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study were 0.004 and 0.386 μg-selenium g−1-diet, respectively.  During the feeding of these 
diets, the body weights of the selenium-deficient diet-fed Tg2576 transgenic mice were not 
significantly different from those of the selenium-adequate diet-fed mice.  Ad libitum 
purified water (> 18 MΩ ⋅ cm) generated by a Milli-Q Biocel system (Millipore Corp., 
Billerica, MA, U.S.A.) was supplied as the drinking water to the mice throughout the feeding 
experiment.   
 
Determination of selenium concentration 
 
The selected organs/tissues were removed from the mice [92-week-old (≈ 21-month-old)] 
under deep ether anesthesia and thoroughly rinsed with saline.  After the removal of 
remaining saline drops with paper towels, an appropriate amount of organs/tissues in the wet 
state was placed in a glass tube, and digested with a one to four mixture by volume of 
perchloric acid and nitric acid.  Selenium concentrations of the digested samples were 
fluorometrically determined using 2,3-diaminonaphtharene (DAN) (Tokyo Chemical Industry 
Co., Ltd., Tokyo, Japan) (excitation wavelength, 375 nm; emission wavelength, 525 nm) 
subsequent to acid digestion using a one to four mixture by volume of perchloric acid and 
nitric acid.22.23  The selenium standard solution [1000 ppm as selenium (IV) dioxide in 0.5 M 
nitric acid] for the fluorometry was obtained from Kanto Chemical Co., Inc. (Tokyo, Japan).  
For the quality control of the determination of the selenium concentrations, organ/tissue 
samples from the conventional mice were spiked with a given volume of the selenium 
standard solution and then subjected to the wet digestion and the subsequent fluorometry.  
Three samples from each diet used in this study were randomly collected, and their selenium 
concentrations were also determined by a procedure similar to that described above.  All 




Preparation of brain slice and its staining with thioflavin T 
 
The average brain weight of the selenium-deficient diet-fed and the selenium-adequate 
diet-fed mice were 0.356 and 0.371 g in the wet state, respectively.  Serial 10-μm-thick brain 
vertical slices (50 pieces for each mouse) were prepared from the middle part of the mice 
brains in a frozen state on a microtome CM1900 (Leica Microsystems, Wetzlar, Germany) 
and then mounted on non-fluorescent slide glasses.  To detect the Aβ plaques, the brain 
slice-immobilized slide glasses were soaked in 10 μM thioflavin T (ThT) (Nacalai Tesque, 
Inc., Kyoto, Japan) 50% ethanol-Milli-Q water solution for 5 min and then sequentially 
washed in three Milli-Q water-filled glass chambers with moving the slides up and down 
gently.  After the removal of remaining water drops, the brain slice-mounted slides were left 
in a lightproof box for ≈ 12 h at room temperature and then subjected to fluorescence 
microscopic evaluation. 
 
Acquisition and analysis of fluorescence image 
 
An inverted microscope BZ-8100 equipped with a GFP-BP filter set (excitation filter, 
450−470 nm; dichroic mirror, 495 nm; emission filter, 515−565 nm) and a 4-fold objective 
lens (numerical aperture, 0.2; working distance, 20 mm) (KEYENCE Corp., Osaka, Japan) 
was used for the fluorescence microscopic observation.  All fluorescence images of the 
ThT-treated brain slices (1360 × 1024 pixels) were acquired for the same exposure time (0.05 
sec) and saved as super fine-grade JPEG files.  The digitized fluorescence images of the 
brain slices were qualitatively analyzed by using MetaMorph (Premier) software (Molecular 
Devices, LLC, Sunnyvale, CA, USA).  The fluorescence intensity above a threshold value 






All data were presented as the mean ± standard error.  Statistical analyses were performed 
using a program PRISM 4 (GraphPad Software, Inc., San Diego, CA, U.S.A.).  Multiple 
mean values were compared by a two-way ANOVA with a Bonferroni post-hoc test with 
treatment and selenium concentration in the diets as factors.  Comparisons were considered 




To examine the selenium status in the Tg2576 transgenic mice after the feeding 
experiment, the selenium concentrations of the selected organs/tissues were determined by the 
fluorescence method using DAN.  The selenium concentrations of the organs/tissues in the 
selenium-deficient diet-fed mice were significantly decreased in comparison to those in the 
selenium-adequate diet-fed mice (Fig. 1).  Typically, the selenium level in the 
selenium-deficient diet-fed mice liver represented 1.7% of that in the selenium-adequate 
diet-fed mice.  The selenium concentration of the brain in the selenium-deficient diet-fed 
mice was also decreased to less than half of that in the selenium-adequate diet-fed mice (43%), 
although the brain retains a relatively high selenium concentration even under conditions of 
persistent dietary selenium deficiency.24   
The Aβ plaques formed in the brain slices were detected using the most widely used 
amyloid staining fluorescent dye ThT whose fluorescence originates only from the dye bound 
to amyloid fibrils.25,26  Typical fluorescence images of the brain slices in the two mice groups 
are represented in Fig. 2.  The fluorescent signals arising from the ThT-treated brain slice of 
the selenium-deficient diet-fed mice (Fig. 2 A) were seemingly more intense in the calvarial 
and temporal regions than those of the selenium-adequate diet-fed mice (Fig. 2 B).  
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Subsequently, the obtained fluorescence images of the brain slices were qualitatively analyzed 
using MetaMorph software (Fig. 3).  The feeding of the selenium-deficient diet to the 
Tg2576 transgenic mice resulted in more than a two-fold increase in the total area of the 
ThT-stained Aβ plaques in the brain slices in comparison to that of the selenium-adequate diet 
(Fig. 3 A).  Similar trends were also observed for the total fluorescence intensity (Fig. 3 B) 
and the number of the ThT-stained Aβ plaques (Fig. 3 C), while no significant difference in 
the average area of the Aβ plaque stained was found between the selenium-deficient and 
selenium-adequate diet-fed mice (Fig. 3 D).  These results demonstrated that the dietary 
selenium-deficiency influences the number, not the size, of the Aβ plaque formed in the brain.  
Consequently, the dietary selenium-deficiency resulted in the significant increase in the 




The Tg2576 transgenic mice overexpress a mutant variant of human amyloid precursor 
protein (APP) (Lys670Asn, Met671Leu) and are well characterized models of AD 
amyloidosis because the mice develop extensive extracellular Aβჼplaque deposits.27  
Increased lipid peroxidation was reported to precede the Aβ plaque formation in the brain of 
the Tg2576 transgenic mice7; Homogenates from the cerebral cortex and hippocampus of the 
Tg2576 transgenic mice had significantly higher levels of a marker (8,12- iso-iPF2a-VI) of 
lipid peroxidation than those from the wild-type mice starting at 8 months old.  In contrast, a 
surge in Aβ peptide levels as well as Aβ deposits in the Tg2576 transgenic mice brains occurs 
later, at 12 months old.  The decreased selenium concentrations in the organs/tissues 
including the brain (Fig. 1) implicated decreases in the concentration of selenoproteins, such 
as GPx-4 and SelP, in the early evolution of Aβ amyloidosis.  GPx-4 heterozygous knockout 
(GPx-4+/–) mice have higher levels of β-secretase activity than age-matched wild-type 
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controls, as a result of up-regulation of β-secretase expression.28  APP transgenic mice with 
reduced brain GPx-4 (APP GPx-4+/–) mice significantly increased amyloid plaques 
compared with APP GPx-4+/+ mice.28  In addition, in our previous studies using normal 
mice, a similar selenium-deficient state occurred due to the 8-week feeding of the 
selenium-deficient diet used in this study.23,29  Thus, the selenium-deficient diet-fed Tg2576 
transgenic mice were also thought to already reach a selenium status as low as that shown in 
Fig. 1, at around 2 months after the feeding of the diets started before the Aβ plaque 
production.  The brain of Tg2576 mice is thought to ubiquitously exhibit an increased level 
of oxidative stress than the wild-type mice, because the sites of amyloid plaque deposition do 
not reflect the regional expression of the Tg2576 transgenes, which are widely expressed in 
neurons throughout the brain.30  Overall, the elevated Aβ plaques deposition in the brain of 
the selenium-deficient diet-fed mice can be explained as a consequence of decreases in the 
selenium concentration.   
The present study demonstrates the elevated Aβ plaque deposition in the brain of the 
selenium-deficient diet-fed Tg2576 transgenic mice, which suggests that the selenium status 
in the brain is associated with the processes of the production and/or the clearance of the Aβ 
peptide from APP.  The selenium-deficiency (or low selenium status) could possibly 
promote the onset and/or progression of AD dementia, if the oligomeric aggregates and/or 
deposits of the Aβ peptide formed in the brain initiate a sequence of events that lead to AD 
dementia.  Thus, the results presented in this study allowed us to suggest that AD has an 
important relation with the selenium status in vivo.   
At the present, the number of AD dementia patients is increasing all over the world, 
currently estimated at 36 million, and will triple by 2050.31  Although many potent Aβ 
peptide-targeted therapeutics (e.g., crenezumab by Genentech, Inc., a humanized anti-Aβ 
peptide-antibody) are now in various stages of development, several candidates (e.g., 
semagacestat by Eli Lilly & Co.) that were purported to reduce its production or aggregation 
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are not yet successful in a Phase III clinical trial.  Preventing cognitive impairment and 
dementia in the elderly is a major public health challenge for this century and all hypotheses 
should be explored.  In addition to the development of effective therapeutics, based on the 
protective roles of selenium from the ROS-mediated injury to the brain, a large prevention 
trial involving 6,600 elderly males in the United States (the Prevention of Alzheimer's Disease 
by Vitamin E and Selenium, PREADVISE) was conducted,32,33 but was unfortunately 
discontinued due to the ironic fact that long-term selenium supplementation with selenized 
yeast could cause type 2 diabetes.34  Antioxidative selenoproteins and/or selenium-containing 
species are one of the factors that may affect the risk of cognitive decline.  Early mechanistic 
roles of antioxidant selenium in the production and/or clearance of the Aβ peptide will be the 
next issues to be investigated, which can provide not only useful information for the 
prevention of the onset of AD dementia but also a potential target for the development of 
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Fig. 1 Selenium concentrations of organs/tissues of Tg2576 transgenic mice at 92-week-old 
after the diet feeding. Black column, selenium-deficient diet-fed mice; gray column, 
selenium-adequate diet-fed mice.  All selenium concentrations in the selenium-deficient 
diet-fed mice were significantly different from those in the selenium adequate diet-fed mice.  
Data express mean ± standard error (n = 5).  Asterisks indicate the organs/tissues that were 



























































































Fig. 2 Typical thioflavin T fluorescence images of the brain slices of the Tg2576 transgenic 
mice.  (A), selenium-deficient diet-fed mice; (B), selenium-adequate diet-fed mice.  White 









Fig. 3 Image analysis of thioflavin T fluorescence in the brain slices of the Tg2576 transgenic 
mice.  (A), total area stained with thioflavin T per brain slice; (B), total fluorescence 
intensity of stained area; (C), the plaque number; (D), ratio of the plaque area to the plaque 
number. Black column, selenium-deficient diet-fed mice; gray column, selenium-adequate 
diet-fed mice.  Data express mean ± standard error (n = 250 specimens for each group).  
Asterisks indicate the parameters that were significantly different (P < 0.05) between the diets.  
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Dietary selenium-deficiency causes elevation of amyloid-β plaque deposition in the brain of 
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